Phase I study of thymidine (dThd) and cisplatin (DDP) given in combination. 1986

D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey

Twenty-three patients with a variety of solid tumors were given thymidine (dThd) at a single dose of 30 g/m2 along with cisplatin (DDP) at escalating doses ranging from 25 to 120 mg/m2. The dThd was administered first, and then after 50% of the total dThd dose had been infused over 1 h, the remaining 50% was given simultaneously with DDP at a separate intravenous site over the next 2 h. Treatment was repeated at 3-week intervals. Gastrointestinal toxicity was dose-limiting and dose-related with increasing dosages of DDP. Central nervous system manifestations occurred in 17% of the patients. Mild myelosuppression was observed only at DDP doses of greater than or equal to 75 mg/m2. Thrombocytopenia was more severe than leukopenia. The maximum tolerated doses on this schedule were 30 g/m2 of dThd and 100 mg/m2 of DDP.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
December 1999, Gan to kagaku ryoho. Cancer & chemotherapy,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
December 1987, American journal of clinical oncology,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
January 1983, Cancer chemotherapy and pharmacology,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
February 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
March 1980, Cancer research,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
October 1994, Gynecologic oncology,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
October 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
October 2001, Clinical cancer research : an official journal of the American Association for Cancer Research,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
January 1990, Cancer chemotherapy and pharmacology,
D F Chiuten, and M Valdivieso, and J A Benvenuto, and B Drewinko, and A Bedikian, and G P Bodey
May 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!